SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 16.41 |
| Enterprise Value ($M) | 10.29 |
| Book Value ($M) | 3.71 |
| Book Value / Share | 1.26 |
| Price / Book | 4.42 |
| NCAV ($M) | 1.52 |
| NCAV / Share | 0.52 |
| Price / NCAV | 10.81 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -4.47 |
| Return on Assets (ROA) | -1.36 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.65 |
| Current Ratio | 1.65 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 8.22 |
| Assets | 10.41 |
| Liabilities | 6.70 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -33.33 |
| Net Income | -4.79 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -24.13 |
| Cash from Investing | -0.68 |
| Cash from Financing | 4.42 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | L5 Capital Inc. | 10.70 | 1.96 | |
| 13G/A | CVI Investments, Inc. | 1.90 | -77.00 | |
| 13G | Copia Fund (Cayman) LP |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 40,992 | 155,526 | 26.36 | |
| 32,906 | 158,255 | 20.79 | |
| 51,226 | 177,878 | 28.80 | |
| 198,858 | 440,324 | 45.16 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AYTU – Aytu BioPharma, Inc. | BCDA – BioCardia, Inc. |
| BCLI – Brainstorm Cell Therapeutics Inc. | BFRG – Bullfrog AI Holdings, Inc. |
| BFRI – Biofrontera Inc. |
Financial data and stock pages provided by
Fintel.io